Ending parasitic diseases through vaccine innovation
A One Health Approach to Protect Humans and Animals
Problem
Intestinal parasites are a global challenge
Parasitic worms are amongst the most common infections worldwide in humans and animals. These infections cause nutritional deficiencies, compromise immunity to co-infecting pathogens, and contribute considerable morbidity to affected people. In animal agriculture, these infections cause BILLIONS in economic losses.
Global impact of intestinal parasites
Infected Globally
Global Prevalence Rate
Annual Economic Losses
Countries Impacted
Mission
We are pioneering a cutting-edge vaccine platform to protect against intestinal parasites, advancing the health and well-being of both humans and animals
Platform Technology
We leverage our novel attenuation procedure in the production of live attenuated vaccines. The OptoVAX platform will lead to:
Standardized Attenuation
Ensures precise, consistent treatment of Ascaris eggs—driving reliable vaccine quality and enhanced safety
Innovative Timing Mechanism
“Tissue arrest” eliminates chronic infection risk while presenting the full antigen spectrum, enabling a powerful protective response
Counteracting Resistance
Addresses the growing failure of conventional anthelmintics, offering a viable alternative to curb resistant parasite strains
Immunisation Scenario
OptoVAX is bringing this immunisation concept to life, using its novel attenuation to protect both humans and animals from parasitic infections.
Our Supporters
Team
Core Team
Leading the charge to bring OptoVAX to life.
Arkadi Kundik
Biotech innovator specializing in translational research, with an MSc in Biology from FU-Berlin. He contributed to the LEISHDNAVAX vaccine for leishmaniasis, developed small-scale bioreactors, and implemented the OptoVAX attenuation process during his PhD.
Ankur Midha
Scientist with over 12 years of research spanning pharmaceutical science, oncology, metabolism, and immunology. Holds a PhD in Biomedical Sciences from FU Berlin and previously practiced pharmacy before transitioning to research. Contributes advanced parasite biology and immunology expertise to OptoVAX.
Scientific Advisors
Guiding research with deep expertise and insight.
Friederike Ebner
Technical University of Munich
School of Life Sciences
Infection Pathogenesis
Oleg Kornilov
Max-Born-Institute
Ultrafast XUV Physics
Thomas Hildebrandt
Leibniz Institute for Zoo and Wildlife Research
Reproduktionsmanagement
Project Lead of
BioRescue
Get in Touch
We are early in our mission to end parasitic diseases through vaccine innovation. We are eager to connect with supporters, collaborators, and investors who are excited about our vision. We are also happy to discuss how the OptoVAX platform may be applied to different use cases.
Call Us
+49 30 838 59250
Email Us
info@optovax.com